Objective was to compare adherence and persistence, as well as direct healthcare costs and utilization, of ospemifene to available local estrogen therapies (LETs). This retrospective database study used integrated medical and pharmacy claims data from the IQVIA Real-World Data Adjudicated Claims - US Database. Ospemifene patients had significantly greater adherence and persistence compared with the other nonring LETs. Ospemifene had the lowest mean outpatient costs of any of the LET cohorts, including the estradiol vaginal ring. Total all-cause healthcare costs were also significantly less for ospemifene patients compared with all other LETs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/cer-2019-0091 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Factors and Response to Neoadjuvant Chemotherapy.
Eur J Breast Health
January 2025
Department of General Surgery, Elazığ Fethi Sekin City Hospital, University of Health Sciences Turkey, Elazığ, Turkey.
Objective: Triple negative breast carcinoma (TNBC) is characterized by the absence of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 receptor expression. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. The aim of this study was to investigate CA IX expression in TNBC and its relationship with treatment effect.
View Article and Find Full Text PDFAssociations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2- Tumors Treated with Adjuvant Hormonal Therapy: A Real-World Study in Croatia.
Breast J
January 2025
Department of Oncology University Hospital Center Split School of Medicine University of Split, Split, Croatia.
Introduction: Disease recurrence in patients with the early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast tumor subtype is particularly challenging to manage due to its complex and very heterogeneous biological nature. Namely, due to primary and secondary resistance, one-quarter of patients with early-stage disease will experience disease recurrence. This variability in the timing of recurrence highlights the need to better identify key biomarkers that could predict therapeutic outcomes and guide personalized treatment strategies for these patients.
View Article and Find Full Text PDFMetabolomic profile and its association with the diagnosis of prostate cancer: a systematic review.
J Cancer Res Clin Oncol
December 2024
Division of Urology/Urooncology, Department of Surgery, School of Medicine, Universidad del Valle, Calle 4 B # 36-00, Cali, Colombia.
Article Synopsis
- The study aimed to explore how a specific metabolomic profile can help diagnose localized prostate cancer by examining various biological samples.
- Researchers analyzed a total of 1248 studies, narrowing down to 14 case-control studies that primarily focused on serum metabolite analysis, revealing significant associations with certain metabolites.
- The findings indicated that disruptions in the metabolism of fatty acids, amino acids, nucleotides, and steroid hormones are linked to localized prostate cancer, with notable increases in amino acids like glutamate and aspartic acid, and decreases in glycine and serine.
Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy.
Transgend Health
December 2024
Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.
Injectable estrogens are options for gender-affirming hormone therapy per guidelines, which suggest intramuscular dosages of 5-30 mg every 2 weeks or 2-10 mg weekly with estradiol cypionate or valerate interchangeably. Data among transgender and gender-diverse patients are limited due to local unavailability and concerns around laboratory assay variability and estradiol (E2) level fluctuation. We note a concerning trend where patients are prescribed high-dose injections based on the guidelines leading to serum E2 levels well above the range recommended in the same guidelines.
View Article and Find Full Text PDFExperience in the Management of Genitourinary Syndrome of Menopause With Fractional CO2 Laser at Dr. Alejandro Dávila Bolaños Military Teaching Hospital in Nicaragua.
Cureus
November 2024
School of Medicine, Hospital Militar Escuela "Dr. Alejandro Dávila Bolaños", Managua, NIC.
Objective: We evaluated the quality of life improvements in patients with genitourinary syndrome of menopause (GSM) who received fractional CO laser therapy at the Gynecology-Obstetrics Department of "Dr. Alejandro Dávila Bolaños" Military School Hospital (HMADB) in Managua, Nicaragua, from June 2022 to October 2023.
Materials And Methods: This descriptive cross-sectional study included 25 GSM patients with contraindications or insufficient response to local estrogen therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!